Literature DB >> 23577743

The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters.

C M Kessler1, A Iorio.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23577743     DOI： 10.1111/hae.12149

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  8 in total

Review 1.  Present and future challanges in the treatment of haemophilia: a clinician's perspective.

Authors:  Pier Mannuccio Mannucci; Massimo Franchini
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

2.  Reflections on the FranceCoag report on inhibitory antibodies to factor VIII in patients with severe hemophilia A.

Authors:  Erik Berntorp; Alfonso Iorio
Journal:  Blood       Date:  2015-06-11       Impact factor: 22.113

3.  Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011.

Authors:  Peter W Collins; Benedict P Palmer; Elizabeth A Chalmers; Daniel P Hart; Ri Liesner; Savita Rangarajan; Katherine Talks; Michael Williams; Charles R M Hay
Journal:  Blood       Date:  2014-10-22       Impact factor: 22.113

Review 4.  A new recombinant factor VIII: from genetics to clinical use.

Authors:  Elena Santagostino
Journal:  Drug Des Devel Ther       Date:  2014-12-12       Impact factor: 4.162

5.  Risk factors for high-titer inhibitor development in children with hemophilia A: results of a cohort study.

Authors:  Susan Halimeh; Christoph Bidlingmaier; Christine Heller; Sven Gutsche; Susanne Holzhauer; Gili Kenet; Karin Kurnik; Daniela Manner; Alfonso Iorio; Ulrike Nowak-Göttl
Journal:  Biomed Res Int       Date:  2013-10-02       Impact factor: 3.411

6.  Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.

Authors:  Thierry Calvez; Hervé Chambost; Roseline d'Oiron; Vincent Dalibard; Virginie Demiguel; Alexandra Doncarli; Yves Gruel; Yoann Huguenin; Patrice Lutz; Chantal Rothschild; Christine Vinciguerra; Jenny Goudemand
Journal:  Haematologica       Date:  2017-10-12       Impact factor: 9.941

7.  Identification of aggregates in therapeutic formulations of recombinant full-length factor VIII products by sedimentation velocity analytical ultracentrifugation.

Authors:  J F Healey; E T Parker; P Lollar
Journal:  J Thromb Haemost       Date:  2018-01-11       Impact factor: 5.824

8.  [Advances in Hemophilia A inhibitors].

Authors:  S X Wang; R C Yang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-05-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.